chlorambucil has been researched along with Smith-Magenis Syndrome in 2 studies
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.
Smith-Magenis Syndrome: Complex neurobehavioral disorder characterized by distinctive facial features (FACIES), developmental delay and INTELLECTUAL DISABILITY. Behavioral phenotypes include sleep disturbance, maladaptive, self-injurious and attention-seeking behaviors. The sleep disturbance is linked to an abnormal circadian secretion pattern of MELATONIN. The syndrome is associated with de novo deletion or mutation and HAPLOINSUFFICIENCY of the retinoic acid-induced 1 protein on chromosome 17p11.2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The treatment landscape of chronic lymphocytic leukemia (CLL) has changed dramatically in the last few years." | 2.58 | Selecting Frontline Therapy for CLL in 2018. ( Jain, N, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, N | 1 |
| Barrientos, JC | 1 |
2 reviews available for chlorambucil and Smith-Magenis Syndrome
| Article | Year |
|---|---|
Selecting Frontline Therapy for CLL in 2018.
Topics: Adenine; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Delet | 2018 |
Sequencing of chronic lymphocytic leukemia therapies.
Topics: Alanine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe | 2016 |